Prognostication of chronic disorders of consciousness using brain functional networks and clinical characteristics
- The Chinese Academy of Sciences, China
- PLA Army General Hospital, China
- Guangzhou General Hospital of Guangzhou Military Command, China
Abstract
Disorders of consciousness are a heterogeneous mixture of different diseases or injuries. Although some indicators and models have been proposed for prognostication, any single method when used alone carries a high risk of false prediction. This study aimed to develop a multidomain prognostic model that combines resting state functional MRI with three clinical characteristics to predict one year outcomes at the single-subject level. The model discriminated between patients who would later recover consciousness and those who would not with an accuracy of around 88% on three datasets from two medical centers. It was also able to identify the prognostic importance of different predictors, including brain functions and clinical characteristics. To our knowledge, this is the first reported implementation of a multidomain prognostic model based on resting state functional MRI and clinical characteristics in chronic disorders of consciousness, which we suggest is accurate, robust, and interpretable.
Data availability
We have provided anonymised demographic and clinical characteristics of the DOC patients in Appendix 1. We have made the analysis pipeline, including fMRI preprocessing, feature calculation and extraction, regression and classification, and the results visualization publicly available. Also, we have uploaded the fMRI signals in each of region of interest for every DOC patient and healthy control involved in this study. Anyone is welcome to download them from GitHub (https://github.com/realmsong504/pDOC).
Article and author information
Author details
Funding
National Natural Science Foundation of China (81471380)
- Ming Song
National Natural Science Foundation of China (91432302,31620103905)
- Tianzi Jiang
The Science Frontier Program of the Chinese academy of Sciences (QYZDJ-SSW-SMC019)
- Tianzi Jiang
National Key R&D Program of China (2017YFA0105203)
- Tianzi Jiang
Beijing Municipal Science and Technology Commission (Z161100000216139)
- Tianzi Jiang
Beijing Municipal Science and Technology Commission (Z161100000216152)
- Ming Song
Beijing Municipal Science and Technology Commission (Z161100000516165)
- Ying Yang
The Guangdong Pearl River Talents Plan Innovative and Entrepreneurial Team (2016ZT06S220)
- Tianzi Jiang
Youth Innovation Promotion Association of the Chinese Academy of Sciences
- Ming Song
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Klaas Enno Stephan, University of Zurich and ETH Zurich, Switzerland
Ethics
Human subjects: The study was approved by the Ethics Committee of the PLA Army General Hospital (protocol no: 2011-097) and the Ethics Committee of the Guangzhou General Hospital of Guangzhou Military Command (protocol no: jz20091287). Informed consent to participate in the study was obtained from the legal surrogates of the patients and from the normal controls.
Version history
- Received: February 23, 2018
- Accepted: August 3, 2018
- Accepted Manuscript published: August 14, 2018 (version 1)
- Version of Record published: September 19, 2018 (version 2)
Copyright
© 2018, Song et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 4,313
- views
-
- 696
- downloads
-
- 57
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Prognostication of chronic disorders of consciousness using brain functional networks and clinical characteristics
eLife 7:e36173.
https://doi.org/10.7554/eLife.36173
Further reading
-
- Medicine
The nuclear receptor, farnesoid X receptor (FXR/NR1H4), is increasingly recognized as a promising drug target for metabolic diseases, including nonalcoholic steatohepatitis (NASH). Protein-coding genes regulated by FXR are well known, but whether FXR also acts through regulation of long non-coding RNAs (lncRNAs), which vastly outnumber protein-coding genes, remains unknown. Utilizing RNA-seq and global run-on sequencing (GRO-seq) analyses in mouse liver, we found that FXR activation affects the expression of many RNA transcripts from chromatin regions bearing enhancer features. Among these we discovered a previously unannotated liver-enriched enhancer-derived lncRNA (eRNA), termed FXR-induced non-coding RNA (Fincor). We show that Fincor is specifically induced by the hammerhead-type FXR agonists, including GW4064 and tropifexor. CRISPR/Cas9-mediated liver-specific knockdown of Fincor in dietary NASH mice reduced the beneficial effects of tropifexor, an FXR agonist currently in clinical trials for NASH and primary biliary cholangitis (PBC), indicating that amelioration of liver fibrosis and inflammation in NASH treatment by tropifexor is mediated in part by Fincor. Overall, our findings highlight that pharmacological activation of FXR by hammerhead-type agonists induces a novel eRNA, Fincor, contributing to the amelioration of NASH in mice. Fincor may represent a new drug target for addressing metabolic disorders, including NASH.
-
- Cell Biology
- Medicine
Chemotherapy is a widely used treatment for a variety of solid and hematological malignancies. Despite its success in improving the survival rate of cancer patients, chemotherapy causes significant toxicity to multiple organs, including the skeleton, but the underlying mechanisms have yet to be elucidated. Using tumor-free mouse models, which are commonly used to assess direct off-target effects of anti-neoplastic therapies, we found that doxorubicin caused massive bone loss in wild-type mice, a phenotype associated with increased number of osteoclasts, leukopenia, elevated serum levels of danger-associated molecular patterns (DAMPs; e.g. cell-free DNA and ATP) and cytokines (e.g. IL-1β and IL-18). Accordingly, doxorubicin activated the absent in melanoma (AIM2) and NLR family pyrin domain containing 3 (NLRP3) inflammasomes in macrophages and neutrophils, causing inflammatory cell death pyroptosis and NETosis, which correlated with its leukopenic effects. Moreover, the effects of this chemotherapeutic agent on cytokine secretion, cell demise, and bone loss were attenuated to various extent in conditions of AIM2 and/or NLRP3 insufficiency. Thus, we found that inflammasomes are key players in bone loss caused by doxorubicin, a finding that may inspire the development of a tailored adjuvant therapy that preserves the quality of this tissue in patients treated with this class of drugs.
